ReviewCurrent transplantation reports2020
Antivirals for COVID-19 in Solid Organ Transplant Recipients.
Review in Current transplantation reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 16 citations in OpenAlex.
- Efficacy and Safety of Remdesivir in Adult Solid Organ Transplant Recipients: A Scoping Review.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Organ Transplantation Preparations During the COVID-19 Pandemic.Florence Nightingale journal of nursing · 2022Article
- Outcomes of SOT Recipients With COVID-19 in Different Eras of COVID-19 Therapeutics.Transplantation direct · 2022Article
- Evolution of Clinical Care in COVID-Infected Solid Organ Transplant Recipients.Current transplantation reports · 2022Review
- Management of COVID-19 in Kidney Transplant Recipients: A Single-Center Case Series.International journal of nephrology · 2022Article
- Coronavirus Disease 2019 and Liver Transplantation: Lessons from the First Year of the Pandemic.Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society · 2021Review
- Immunosuppression practices during the COVID-19 pandemic: A multinational survey study of transplant programs.Clinical transplantation · 2021Article
- COVID-19 and Effect on Liver Transplant.Current treatment options in gastroenterology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
purpose of reviewTo evaluate the critical studies published so far on the most promising antiviral therapies for COVID-19, with particular emphasis on any solid organ transplant-specific information. RECENT
findingsAlthough the literature is increasing exponentially, most clinical trials have been preliminary, thus lacking robust evidence to support many of the drugs discussed here. The main exception is remdesivir, for which several trials have been published supporting its use for patients with severe COVID-19. No solid organ transplant-specific data on remdesivir or other antiviral therapies have been published so far. SUMMARY: While further studies are urgently needed, in particular those specific to solid organ transplant recipients, the evidence so far only supports the use of remdesivir for patients with severe COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.